Last reviewed 2026-04-20 · How we verify

UCMSC

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis (PHASE1, PHASE2)
• National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Phase I Study on Safety and Efficacy of Mesenchymal Stem-Cell (MSC) Therapy in Non-Viral Acute-on-Chronic Liver Failure (ACLF) (PHASE1)
• National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial (PHASE2)
• National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial (PHASE3)
• Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants (PHASE2)
• Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study (PHASE1, PHASE2)
• UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia (PHASE1)
• Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• UCMSC CI brief — competitive landscape report
• UCMSC updates RSS · CI watch RSS
• Fuzhou General Hospital portfolio CI